Cyclooxygenase 2 Inhibitors

"Cyclooxygenase 2 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.

Descriptor ID	D052246
MeSH Number(s)	D27.505.519.389.310.500 D27.505.696.663.850.014.040.500.500.500 D27.505.954.158.030.500.500 D27.505.954.329.030.500.500
Concept/Terms	Cyclooxygenase 2 Inhibitors Cyclooxygenase 2 Inhibitors Inhibitors, Cyclooxygenase 2 Cyclooxygenase-2 Inhibitors Inhibitors, Cyclooxygenase-2 Coxibs COX-2 Inhibitors COX 2 Inhibitors Inhibitors, COX-2 COX2 Inhibitors Inhibitors, COX2

Below are MeSH descriptors whose meaning is more general than "Cyclooxygenase 2 Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Cyclooxygenase Inhibitors [D27.505.519.389.310]
Cyclooxygenase 2 Inhibitors [D27.505.519.389.310.500]
Physiological Effects of Drugs [D27.505.696]
Peripheral Nervous System Agents [D27.505.696.663]
Sensory System Agents [D27.505.696.663.850]
Analgesics [D27.505.696.663.850.014]
Analgesics, Non-Narcotic [D27.505.696.663.850.014.040]
Anti-Inflammatory Agents, Non-Steroidal [D27.505.696.663.850.014.040.500]
Cyclooxygenase Inhibitors [D27.505.696.663.850.014.040.500.500]
Cyclooxygenase 2 Inhibitors [D27.505.696.663.850.014.040.500.500.500]
Therapeutic Uses [D27.505.954]
Anti-Inflammatory Agents [D27.505.954.158]
Anti-Inflammatory Agents, Non-Steroidal [D27.505.954.158.030]
Cyclooxygenase Inhibitors [D27.505.954.158.030.500]
Cyclooxygenase 2 Inhibitors [D27.505.954.158.030.500.500]
Antirheumatic Agents [D27.505.954.329]
Anti-Inflammatory Agents, Non-Steroidal [D27.505.954.329.030]
Cyclooxygenase Inhibitors [D27.505.954.329.030.500]
Cyclooxygenase 2 Inhibitors [D27.505.954.329.030.500.500]

Below are MeSH descriptors whose meaning is related to "Cyclooxygenase 2 Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Cyclooxygenase 2 Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cyclooxygenase 2 Inhibitors" by people in this website by year, and whether "Cyclooxygenase 2 Inhibitors" was a major or minor topic of these publications.

Bar chart showing 22 publications over 11 distinct years, with a maximum of 3 publications in 2002 and 2003 and 2006 and 2010 and 2012

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2002	0	3	3
2003	0	3	3
2004	0	2	2
2005	0	1	1
2006	3	0	3
2010	2	1	3
2011	0	1	1
2012	0	3	3
2013	0	1	1
2016	1	0	1

Below are the most recent publications written about "Cyclooxygenase 2 Inhibitors" by people in Profiles.

Cleary JM, Mamon HJ, Szymonifka J, Bueno R, Choi N, Donahue DM, Fidias PM, Gaissert HA, Jaklitsch MT, Kulke MH, Lynch TP, Mentzer SJ, Meyerhardt JA, Swanson RS, Wain J, Fuchs CS, Enzinger PC. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer. 2016 07 13; 16:468.

View in: PubMed
Holt HD, Hinkle DM, Falk NS, Fraunfelder FT, Fraunfelder FW. Human papilloma virus vaccine associated uveitis. Curr Drug Saf. 2014 Mar; 9(1):65-8.

View in: PubMed
Leoutsakos JM, Bartlett AL, Forrester SN, Lyketsos CG. Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example. Alzheimers Dement. 2014 Mar; 10(2):152-61.

View in: PubMed
Solomon DH, Rassen JA, Kuriya B, Chen L, Harrold LR, Graham DJ, Lewis JD, Lii J, Liu L, Griffin MR, Curtis JR. Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis. 2013 Nov; 72(11):1813-8.

View in: PubMed
Baris D, Karagas MR, Koutros S, Colt JS, Johnson A, Schwenn M, Fischer AH, Figueroa JD, Berndt SI, Han S, Beane Freeman LE, Lubin JH, Cherala S, Cantor KP, Jacobs K, Chanock S, Chatterjee N, Rothman N, Silverman DT. Nonsteroidal anti-inflammatory drugs and other analgesic use and bladder cancer in northern New England. Int J Cancer. 2013 Jan 01; 132(1):162-73.

View in: PubMed
Guo S, Qiu P, Xu G, Wu X, Dong P, Yang G, Zheng J, McClements DJ, Xiao H. Synergistic anti-inflammatory effects of nobiletin and sulforaphane in lipopolysaccharide-stimulated RAW 264.7 cells. J Agric Food Chem. 2012 Mar 07; 60(9):2157-64.

View in: PubMed
Boyer KA, Angst MS, Asay J, Giori NJ, Andriacchi TP. Sensitivity of gait parameters to the effects of anti-inflammatory and opioid treatments in knee osteoarthritis patients. J Orthop Res. 2012 Jul; 30(7):1118-24.

View in: PubMed
Gurwitz JH. NSAIDs and atrial fibrillation. BMJ. 2011 Jul 04; 343:d2495.

View in: PubMed
Carothers AM, Davids JS, Damas BC, Bertagnolli MM. Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis. Cancer Res. 2010 Jun 01; 70(11):4433-42.

View in: PubMed
Davids JS, Carothers AM, Damas BC, Bertagnolli MM. Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis. Cancer Prev Res (Phila). 2010 Mar; 3(3):348-58.

View in: PubMed

People

Explore

Similar Concepts

Top Journals